Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700035 | 1.00 | ALDH1A1 (0.50) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL2552304 | 1.00 | ALDH1A1 (0.50) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL2552670 | 1.00 | ALDH1A1 (0.50) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL2549349 | 1.00 | ALDH1A1 (0.50) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL16831416 | 0.92 | ALDH1A1 (0.43) | ALDH1A1PTPN1HCAR2TBXAS1LPAR3 | |
| SCHEMBL5010354 | 0.92 | ALDH1A1 (0.43) | ALDH1A1PTPN1HCAR2TBXAS1LPAR3 | |
| SCHEMBL9423105 | 0.86 | TBXAS1 (0.39) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL7543228 | 0.85 | PTPN1 (0.41) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL7543224 | 0.85 | PTPN1 (0.41) | ALDH1A1PTPN1HCAR2TBXAS1LPAR2 | |
| SCHEMBL4888380 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3269802-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | Bluebird Bio, Inc. (US) | 2018-01-17 | — | — | EP | claimed |
| EP-2760994-B1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO INC (US) | 2017-05-31 | — | — | EP | claimed |
| US-20150216903-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO, INC. (US) | 2015-08-06 | — | — | US | claimed |
| US-20140234278-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | GENETIX BIOTHERAPEUTICS INC. | 2014-08-21 | — | — | US | claimed |
| EP-2760994-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | Bluebird Bio, Inc. (US) | 2014-08-06 | — | — | EP | claimed |
| WO-2014026110-A2 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO, INC. (US) | 2014-02-13 | — | — | WO | claimed |
| WO-2013049615-A1 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | BLUEBIRD BIO, INC. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20090285786-A1 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-11-19 | — | — | US | claimed |
| JP-2009530408-A | — | — | 2009-08-27 | — | — | JP | claimed |
| EP-1999255-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | The Children's Medical Center Corporation (US) | 2008-12-10 | — | — | EP | claimed |
| WO-2007112084-A9 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDRENS MEDICAL CENTER (US) | 2007-11-22 | — | — | WO | claimed |
| WO-2007112084-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-10-04 | — | — | WO | claimed |
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | BLUEBIRD BIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) | 2025-09-18 | — | — | US | disclosed |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | ORCHARD THERAPEUTICS EUROPE LTD (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12234476-B2 | VCN enhancer compositions and methods of using the same | BLUEBIRD BIO, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20090285786-A1 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1999255-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | The Children's Medical Center Corporation (US) | 2008-12-10 | — | — | EP | disclosed |
| WO-2007112084-A9 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDRENS MEDICAL CENTER (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007112084-A2 | METHOD TO MODULATE HEMATOPOIETIC STEM CELL GROWTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022403-A1 | VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME | PTGES2, POLN, HPGDS | ALDH1A1 1918/4885PTPN1 4736/4885HCAR2 4209/4885 |
| US-20250134927-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES | CD4, CD74, HLA-DRB1 | ALDH1A1 2029/4885PTPN1 686/4885HCAR2 1150/4885 |
| US-20250290097-A1 | COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS | PHAX, CD44, HCLS1 | ALDH1A1 2544/4885PTPN1 2968/4885HCAR2 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.